Assembly of 4-Aminoquinolines via Palladium
Catalysis: A Mild and Convenient Alternative to
SNAr Methodology
Brandon J. Margolis,* Kimberly A. Long,† Dana L. T. Laird,
J. Craig Ruble, and Shon R. Pulley
Lilly Research Laboratories, Eli Lilly and Company,
Indianapolis, Indiana 46285
FIGURE 1. Marketed drugs/drug candidates containing a 4-AQ core.
chloro). The SNAr reaction is often carried out neat, or in the
presence of phenol, at elevated temperatures (∼100-160 °C).5
Isolating the desired product can be difficult since the reaction
mixtures tend to solidify upon cooling and require an acid/base
extraction to remove the excess phenol. Interest in these
structures prompted us to explore palladium-catalyzed amination
chemistry6 as a mild and convenient alternative to classical
methodologies for the synthesis of 4-AQ’s. In these cases, one
can simply adsorb the crude reaction mixture onto silica gel
and purify directly, thus avoiding a formal aqueous workup and
making this attractive for small scale or parallel reactions.
Encouraged by an initial result with Pd(OAc)2/DPEphos/K3-
PO4 in toluene to couple 4-bromoquinoline (4a) with a primary
alkylamine, a series of iterative screens to optimize this catalyst
system were undertaken in a controlled fashion selecting the
R-methyl amine (6) present in chloroquine as a representative
amine in these studies (eq 1).
ReceiVed October 18, 2006
4-Aminoquinolines, classically prepared via SNAr chemistry
from an amine and 4-haloquinoline, are important scaffolds
in medicinal chemistry. Interest in these compounds prompted
us to explore palladium catalysis as an alternative to the
existing methods for their preparation. Initial results followed
by an iterative screening paradigm confirmed Pd(OAc)2/
DPEphos/K3PO4 as a mild and convenient alternative for the
formation of the C-N bond in 4-aminoquinolines. A
description of the screen and the scope of this methodology
are discussed herein.
There are numerous therapeutic agents which highlight the
significance of 4-aminoquinolines (4-AQ’s) as important scaf-
folds in medicinal chemistry, including: those able to treat
malaria,1 cancer,2 gastric disorders,3 and those able to activate
targets in the central nervous system (Figure 1).4
Recognizing that an exhaustive matrix evaluation was im-
practical given the number of possible permutations, we took a
three-step approach in the following order: (1) solvents, (2)
bases, and (3) phosphine ligands. The decision was made to
use only one palladium source [precatalyst Pd(II)(OAc)2] for
this work. In addition, for convenience, an artificial end point
of 18 h was imposed for the reactions. For the base and
phosphine screens, reactions were analyzed by analytical HPLC,
and yields were calculated relative to an internal standard (IS).7
Using the Pd(OAc)2/DPEphos/K3PO4 system, several solvents
including dioxane, PhMe, and DME were evaluated. Either
dioxane or PhMe was found to be optimal (these results were
not quantitated). Of these, dioxane was chosen for further study
mainly for its relatively low boiling point and low UV cutoff.
A small survey of bases commonly used in palladium-catalyzed
aminations was preformed as the second iteration; K3PO4 was
found to be optimal for this system (Table 1).
Historically, the assembly of 4-AQ’s involves a SNAr reaction
between the requisite amine and a 4-haloquinoline (usually
† Participant in the 2006 Lilly Corporate Summer Intern Program.
(1) Chloroquine exemplifies a class of 4-AQ antimalarial agents. Also
see: (a) O’Neill, P. M.; Ward, S. A.; Berry, N. G.; Jeyadevan, J. P.; Biagini,
G. A.; Asadollaly, E.; Park, K. B.; Bray, P. G. Curr. Top. Med. Chem.
2006, 6 (5), 479-507. (b) Madrid, P. B.; Sherrill, J.; Liou, A. P.; Weisman,
J. L.; DeRisi, J. L.; Guy, R. K. Bioorg. Med. Chem. Lett. 2005, 15, 1015-
1018. (c) Pradines, B.; Tall, F.; Ramiandrasoa, A.; Spiegel, C.; Sokhna,
C.; Fusai, J.; Mosnier, J.; Daries, W.; Trape, J. F.; Kunesch, G.; Parzy, D.;
Rogier, C. J. Antimicrob. Chemother. 2006, 57 (6), 1093-1099. (d) Biot,
C.; Daher, W.; Chavain, N.; Fandeur, T.; Khalife, J.; Dive, D.; De Clercq,
E. J. Med. Chem. 2006, 49 (9), 2845-2849.
(2) Ruchelman, A. L.; Singh, S. K.; Abhijit, R.; Wu, X. H.; Yang, J.;
Li, T.; Liu, A.; Liu, L. F.; LaVoie, E. J. Bioorg. Med. Chem. 2003, 11,
2061-2073.
(3) SKF-97574 was in Phase III clinical trials for the treatment of upper
gastrointestinal ulcers. (a) Leach, C. A.; Brown, T. H.; Ife, R. J.; Keeling,
D. J.; Parsons, M. E.; Theobald, C. J.; Wiggall, K. J. J. Med. Chem. 1995,
38 (14), 2748-2762. (b) Atkins, R. J.; Breen, G. F.; Crawford, L. P.; Grinter,
T. J.; Harris, M. A.; Hayes, J. F; Moores, C. J.; Saunders, R. N.; Share, A.
C.; Walsgrove, T. C.; Wicks, C. Org. Process Res. DeV. 1997, 1, 185-
197.
(5) (a) Surrey, A. R.; Hammer, H. F. J. Am. Chem. Soc. 1946, 68, 113-
116. (b) Surrey, A. R.; Cutler, R. A. J. Am. Chem. Soc. 1951, 73, 2623-
2626.
(4) Tacrine is approved to treat the symptoms of Alzheimer’s disease.
For a series of 4-aminoquinoline-based H3 antagonists, see: Turner, S. C.;
Esbenshade, T. A.; Bennani, Y. L.; Hancock, A. A. Bioorg. Med. Chem.
Lett. 2003, 13, 2131-2135.
(6) (a) Hartwig, J. F. In Handbook of Organopalladium Chemistry for
Organic Synthesis; Negiahi, E. I., Ed.; Wiley-Interscience: New York, 2002;
Vol. 1, p 1051. (b) Muci, A. R.; Buchwald, S. L. Top. Curr. Chem. 2002,
219, 131-209.
10.1021/jo062168u CCC: $37.00 © 2007 American Chemical Society
Published on Web 02/13/2007
2232
J. Org. Chem. 2007, 72, 2232-2235